tiprankstipranks
Blurbs

Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group

Maxim Group analyst Naz Rahman maintained a Buy rating on Quoin Pharmaceuticals (QNRXResearch Report) yesterday and set a price target of $2.00. The company’s shares opened today at $0.53.

Rahman covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Quoin Pharmaceuticals, and scPharmaceuticals. According to TipRanks, Rahman has an average return of -11.7% and a 31.13% success rate on recommended stocks.

Currently, the analyst consensus on Quoin Pharmaceuticals is a Moderate Buy with an average price target of $4.00, implying a 654.72% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $6.00 price target.

See today’s best-performing stocks on TipRanks >>

QNRX market cap is currently $2.57M and has a P/E ratio of -0.02.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

Read More on QNRX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles